Toggle navigation
TWText.com
TWText.com
faq
Contact US
Follow US
#LCSM
Nathan A. Pennell MD, PhD, FASCO
n8pennell
I messed up my poster so attaching slides here (Abstract 9529: A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with
Read more
Jill
jillfeldman4
1/Fantastic talk by @CharuAggarwalMD on molecular/biomarker testing & data. Why is it important? Targeted therapy improves outcomes, IO does not work for everyone & IO b4 TKIs has been associated
Read more
Clive Peedell
cpeedell
Can we achieve similar outcomes for lung #SABR in non-academic institutions compared to the major academic centres? This was an important question posed by @drdavidpalma Suresh Senan & @FJLagerwaard. This
Read more
Stephen V Liu
StephenVLiu
#ESMO20 Much anticipated results from CodeBreaK100: AMG 510 (sotorasib) in #KRAS G12C #NSCLC by @DavidHongMD building on exciting data seen over the past two years for this huge unmet need.
Read more
Nathan A. Pennell MD, PhD, FASCO
n8pennell
THREAD: I have heard a lot of self-righteous indignation about how we would be bankrupting the system with adjuvant targeted treatment for EGFR mutation+ NSCLC pts, so let's take a
Read more
Uppity Cancer Pt
UppityCancerP
If you end up at the ER, don't say that you have terminal cancer. This will close doors. Thank you @drdonsdizon #bcsm #lcsm #bccww #covid19ncancer https://twitter.com/drdonsdizon/status/1248948968136093699 Who else wants to
Read more
Drew Moghanaki
DrewMoghanaki
A few years before the RTOG 0236 reported a local tumor control rate of 91% with lung SBRT (2010), the Z4033 trial explored RFA as an alternative. The key findings
Read more
Myvizhi Esai Selvan
EsaiMyvizhi
Excited to share that our work “Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk” is now published in JTO: 1/7 @JTOonline@SinaiGenetics @IcahnInstitute #lcsm https://pubmed.ncbi.nlm.nih.gov/32866655/ O
Read more
Kartik Sehgal
KartikSehgal_MD
Delay/extension of pembro-based Rx for advanced NSCLC expected #COVID19. In preprint @medRxiv, our experience with outcomes in patients who received atleast ≥4 cycles and had delays/extensions. Results hypothesis-generating only but
Read more
Patrick Forde
FordePatrick
Today at #AACR21 I was honored to present results of the phase 3 CheckMate 816 neoadjuvant chemo-nivo lung cancer trial on behalf of all the colleagues, patients & families who
Read more
Santiago Viteri
DrViteri
I am honored to be part of this piece of the lung cancer story. Tepotinib in NSCLC with MET exon 14 skipping mutations. #NSCLC #METex14 #Tepotinib #LCSM https://www.nejm.org/doi/full/10.1056/NEJMoa2004407?source=nejmtwitter&medium=organ
Read more
Liz Salmi
TheLizArmy
How might we design a palliative care model for people with brain tumors AND their care partners?1st: Define quality of life (QoL)This study used Twitter to better understand how people
Read more
Mike Thompson, MD, PhD, FASCO
mtmdphd
1/ [THREAD] Timeline @ASCO Social Media & Analyses [Updated: May 22, 2020] #socialoncology #socpharm #ASCO20 #ASCO20 Tweeps -- remember to Report (& Block) SPAMmers using oncology hashtags. Clean
Read more